Axial Spondylarthritis (axSpA), Psoriatic Arthritis (PsA)
Conditions
Brief summary
This observational study will target patients with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) who have started treatment with bimekizumab, upadacitinib, risankizumab, guselkumab, or a tumour necrosis factor-alpha inhibitor (e.g., adalimumab or etanercept) at NHS hospitals in the United Kingdom. Information from patients' medical records will be collected, and patients will complete surveys about their experiences with their treatment. The study will look at treatment effectiveness from both healthcare professionals' and patients' points of view.
Detailed description
Patient experience surveys will be administered prospectively throughout the study period, whereas the review of patients' medical records will be conducted retrospectively towards the end of the study period.
Interventions
OTHERobservational study
This is an observational study based on existing treatments prescribed prior to inclusion. No interventions are given as part of this research.
Sponsors
Adelphi Real World
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Participant has a clinical diagnosis of axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA). * Participant has been prescribed advanced therapy within one month prior to enrolment in the study, to treat their axSpA or PsA. * Participant is aged 18 years or older at enrolment.
Exclusion criteria
-Participation in a clinical trial at enrolment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of participants that have achieved Low Disease Activity (LDA) at 12 months. | At 12 months |
| Number of participants that have achieved Minimal Disease Activity (MDA) at 12 months. | At 12 months |
| Change from baseline in PROM scores at 12 months. | At 12 months |
Countries
United Kingdom
Contacts
Primary ContactSpA Extend Team
Outcome results
None listed